Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tacrolimus dry powder inhalation - TFF Pharmaceuticals

Next Previous
Drug Profile

Tacrolimus dry powder inhalation - TFF Pharmaceuticals

Alternative Names: Tac-Lac Inhalation Powder; Tacrolimus inhalation powder - TFF Pharmaceuticals; TFF TAC-LAC; TFF-TAC

Latest Information Update: 29 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator TFF Pharmaceuticals
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Antiglaucomas; Antipsoriatics; Antirheumatics; Eye disorder therapies; Lactones; Macrolides; Skin disorder therapies; Urologics; Vascular disorder therapies
  • Mechanism of Action Bone morphogenetic protein receptor type II modulators; Calcineurin inhibitors; Cytokine inhibitors; Immunosuppressants; T cell activation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Lung transplant rejection
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Asthma; Lung transplant rejection

Most Recent Events

  • 03 Mar 2025 Discontinued - Phase-II for Lung transplant rejection (Prevention) in Australia (Inhalation)
  • 03 Mar 2025 Discontinued - Preclinical for Asthma in USA (Inhalation)
  • 06 Aug 2024 Updated efficacy and safety data from a phase II trial in Lung transplant rejection released by TFF Pharmaceuticals

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top